Asenapine review, part II: clinical efficacy, safety and tolerability (Q38209081)

31 August 2017

title

Asenapine review, part II: clinical efficacy, safety and tolerability (English)

1 reference

31 August 2017

1

1 reference

31 August 2017

language of work or name

English

0 references

publication date

3 May 2014

1 reference

Expert Opinion on Drug Safety

31 August 2017

published in

1 reference

31 August 2017

volume

13

1 reference

31 August 2017

issue

6

1 reference

31 August 2017

page(s)

803-830

1 reference

Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Asenapine versus olanzapine in acute mania: a double-blind extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Review: 15 antipsychotic drugs are more effective than placebo for the treatment of schizophrenia, but vary in their tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Asenapine treatment and health-related quality of life in patients experiencing bipolar I disorder with mixed episodes: post-hoc analyses of pivotal trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Early improvement as a predictor of acute treatment outcome in manic or mixed episodes in bipolar-1 disorder: a pooled, post hoc analysis from the asenapine development program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Comparison of QTc data analysis methods recommended by the ICH E14 guidance and exposure-response analysis: case study of a thorough QT study of asenapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Evaluation of the clinical efficacy of asenapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Asenapine: a clinical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Management of schizophrenia: clinical experience with asenapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

The role of asenapine in the treatment of manic or mixed states associated with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Asenapine: a review of acute and extension phase data in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Asenapine: a review of its use in the management of mania in adults with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Use of asenapine in clinical practice for the management of bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Asenapine in bipolar I disorder: evidence and place in patient management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Asenapine maleate: a new drug for the treatment of schizophrenia and bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Asenapine: a clinical review of a second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Asenapine: a synthesis of efficacy data in bipolar mania and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

Short-term safety and pharmacokinetic profile of asenapine in older patients with psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.908183

10.1517/14740338.2014.908183

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference